SML0720

Methazolamide

≥98% (HPLC), carbonic anhydrase inhibitor, powder

• Synonym(s): 5-Acetylimino-4-methyl-·2-1,3,4-thiadiazoline-2-sulfonamide, N-(4-Methyl-2-sulfamoyl-Δ²-1,3,4-thiadiazolin-5-ylidene) acetamide, L 584601, N-[5-(Aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3H)-ylidene]acetamide
• Empirical Formula (Hill Notation): C₅H₈N₄O₃S₂
• CAS Number: 554-57-4
• Molecular Weight: 236.27
• NACRES: NA.77
• PubChem Substance ID: 329825590
• UNSPSC Code: 12352200
• EC Number: 209-066-7
• MDL number: MFCD00083416
• Assay: ≥98% (HPLC)
• Form: powder
• Quality level: 100
• Storage condition: protect from light

Properties

• Product Name: Methazolamide, ≥98% (HPLC)
• Quality Level: 100
• assay: ≥98% (HPLC)
• form: powder
• storage condition: protect from light
• color: white to beige
• mp: 208 °C (dec.) (lit.)
• solubility: DMSO: 20 mg/mL, clear
• storage temp.: 2-8°C
• SMILES string: CN1N=C(S\C1=N\C(C)=O)S(N)(=O)=O

Description

Biochem/physiol Actions

Cell-permeable and potent carbonic anhydrase (CA) inhibitor

Methazolamide is a cell-permeable and potent carbonic anhydrase (CA) inhibitor that is used in the treatment of glaucoma. Methazolamide is an insulin sensitizer that reduces hepatic glucose generation in animal models.

Methazolamide has a plasma half-life of 14 hours in humans. Methazolamide has relatively good lipid solubility and low plasma protein binding ability. Thus, it diffuses into tissues and fluids much more readily than acetazolamide, another carbonic anhydrase inhibitor. Methazolamide has less side effects than acetazolamide.

Other Notes

Light sensitive

Safety Information

• pictograms: GHS08,GHS07
• signalword: Warning
• hcodes: H302 + H312 + H332,H351
• pcodes: P202 - P280 - P301 + P312 - P302 + P352 + P312 - P304 + P340 + P312 - P308 + P313
• Hazard Classifications: Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Carc. 2
• Storage Class: 11 - Combustible Solids
• wgk: WGK 3